-
Effects of Full-Spectrum Cannabis Oil with a Cannabidiol:Tetrahydrocannabinol 2:1 Ratio on the Mechanisms Involved in Hepatic Steatosis and Oxidative Stress in Rats Fed a Sucrose-Rich Diet. Med. Cannabis Cannabinoids Pub Date : 2023-11-15 Valentina Degrave,Michelle Berenice Vega Joubert,Paola Ingaramo,Daniela Sedan,Darío Andrinolo,María Eugenia D'Alessandro,María Eugenia Oliva
Introduction This study aimed to analyze the effects of cannabis oil (cannabidiol:tetrahydrocannabinol [CBD:THC], 2:1 ratio) on the mechanisms involved in hepatic steatosis and oxidative stress in an experimental model of metabolic syndrome (MS) induced by a sucrose-rich diet (SRD). We hypothesized that noninvasive oral cannabis oil administration improves hepatic steatosis through a lower activity
-
Improved Post-Traumatic Stress Disorder Symptoms and Related Sleep Disturbances after Initiation of Medical Marijuana Use: Evidence from a Prospective Single Arm Pilot Study. Med. Cannabis Cannabinoids Pub Date : 2023-11-13 Krishna Vaddiparti,Yiyang Liu,Sarah Bottari,Carly Crump Boullosa,Zhi Zhou,Yan Wang,John Williamson,Robert L Cook
Introduction Post-traumatic stress disorder (PTSD) is a debilitating disorder experienced by a subgroup of individuals following a life-threatening trauma. Several US states have passed laws permitting the medical use of marijuana (MMJ) by individuals with PTSD, despite very little scientific indication on the appropriateness of marijuana as a therapy for PTSD. This prospective pilot study of adults
-
Absorption and Bioavailability of Novel UltraShear Nanoemulsion of Cannabidiol in Rats. Med. Cannabis Cannabinoids Pub Date : 2023-11-07 Mahmoud A ElSohly,Iram Shahzadi,Waseem Gul
Introduction Cannabidiol (CBD) has several potential benefits and therapeutic uses, especially in pain, inflammation, and anxiety. CBD has high hydrophobicity and very low solubility in water. CBD has also shown exceptionally low oral-gastrointestinal (oral-GI) bioavailability. In this study, we aimed to examine the oral gastrointestinal absorption and subsequent bioavailability of CBD in a nanoemulsion
-
Effects of Two Cannabidiol Oil Products on Self-Reported Stress Relief: A Quasi-Experimental Study. Med. Cannabis Cannabinoids Pub Date : 2023-11-06 Mohammed Faraj,Tyler Dautrich,Leslie Lundahl,Hilary Marusak
Introduction Estimated rates of past-month cannabidiol (CBD) use in the general public are 13-26% and emerging research examines CBD as a potential adjunct treatment for several medical conditions, including stress-related disorders (e.g., depression, anxiety, and chronic pain). However, little is known about the effects of different CBD products on self-reported stress. The present study compared
-
Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health. Med. Cannabis Cannabinoids Pub Date : 2023-10-27 Fabio Turco,Viola Brugnatelli,Raquel Abalo
The maintenance of homeostasis in the gastrointestinal (GI) tract is ensured by the presence of the endocannabinoid system (ECS), which regulates important physiological activities, such as motility, permeability, fluid secretion, immunity, and visceral pain sensation. Beside its direct effects on the GI system, the ECS in the central nervous system indirectly regulates GI functions, such as food intake
-
Tetrahydrocannabinol in Pediatrics: Room for Improvement? Med. Cannabis Cannabinoids Pub Date : 2023-10-18 Charlotte de Gier,Christian Scharinger,Rosa H Stark,Philipp Steurer,Claudia M Klier
Introduction The use of medical cannabis in pediatrics is not common in clinical practice, and there is a lack of prospective studies, especially in pediatric subpopulations. This study aimed to provide data on the off-label administration of tetrahydrocannabinol (∆9-THC) in a pediatric tertiary center in Austria. Methods A retrospective data analysis was performed to assess the use of ∆9-THC at the
-
Medical Cannabis Alleviates Chronic Neuropathic Pain Effectively and Sustainably without Severe Adverse Effect: A Retrospective Study on 99 Cases. Med. Cannabis Cannabinoids Pub Date : 2023-08-17 Lan Kluwe,Christian Scholze,Lisa Marie Schmidberg,Julian Lukas Wichmann,Mihail Gemkov,Martin Julian Keller,Said C Farschtschi
Introduction Medical cannabis may provide a treatment option for chronic neuropathic pain. However, empirical disease-specific data are scarce. Methods This is a retrospective observational study including 99 patients with chronic neuropathic pain. These patients received medical cannabis by means of inhaling dried flowers with tetrahydrocannabinol content of <12-22% at a maximal daily dose of 0.15-1
-
Long-Term, Self-Dosing CBD Users: Indications, Dosage, and Self-Perceptions on General Health/Symptoms and Drug Use. Med. Cannabis Cannabinoids Pub Date : 2023-08-16 Robert Kaufmann,Amber Harris Bozer,Amanda Kube Jotte,Keith Aqua
Introduction Self-dosing of off-the-shelf cannabidiol (CBD) for a myriad of health conditions is common in the USA. These CBD products are often mislabeled, suggesting that much less or much more CBD is being consumed than indicated on the label. This study examined the relationship between long-term self-dosing of CBD and (a) indications and, when a verified concentration of CBD is being consumed
-
Tolerability and Efficacy of a 10:25 Preparation of Δ9-Tetrahydrocannabinol and Cannabidiol for Treatment of Chronic Back or Neck Pain: A Multiple-Dose Escalation Study. Med. Cannabis Cannabinoids Pub Date : 2023-07-07 Paul Glare,Richard Chye,Mark Bloch,Mark Arya,Andrew Moore,John Montgomery
Introduction The aim was to demonstrate the safety and tolerability of cannabidiol (CBD) with Δ9-THC in patients with moderate to severe chronic back or neck pain unresponsive to over-the-counter non-opioid analgesics. Methods This was a non-randomized, single-arm, open-label study. Participants received escalating doses of an oromucosal-administered combination containing 10 mg/mL of Δ9-THC, 25 mg/mL
-
Protocol of a Combined Cohort and Cross-Sectional Study of Persons Receiving Medical Cannabis in Florida, USA: The Medical Marijuana and Me (M3) Study. Med. Cannabis Cannabinoids Pub Date : 2023-05-09 Ruba Sajdeya,Hannah J Fechtel,Gabriel Spandau,Amie J Goodin,Joshua D Brown,Sebastian Jugl,Nicole E Smolinski,Almut G Winterstein,Robert L Cook,Yan Wang
Significant knowledge gaps regarding the effectiveness and safety of medical cannabis (MC) create clinical challenges for MC physicians, making treatment recommendations and patients choosing treatment among the growing number of options offered in dispensaries. Additionally, data describing the characteristics of people who use MC and the products and doses they receive are lacking. The Medical Marijuana
-
Climbing the Evidence Pyramid: Dosing Considerations for Medical Cannabis in the Management of Chronic Pain Med. Cannabis Cannabinoids Pub Date : 2023-04-26 Sebastian Jugl, Amie J. Goodin, Joshua D. Brown
Med Cannabis Cannabinoids 2023;6:41–45
-
The Effects of Long-Term Self-Dosing of Cannabidiol on Drowsiness, Testosterone Levels, and Liver Function Med. Cannabis Cannabinoids Pub Date : 2023-03-22 Robert Kaufmann, Amber Harris Bozer, Amanda Rose Kube Jotte, Keith Aqua
Introduction: Previous research indicated that cannabidiol (CBD) may result in low levels of male total testosterone (TT), elevations in liver tests (LTs), and daytime drowsiness (DD). We investigated the prevalences of TT and LT in a large adult sample self-administering CBD and determined the effect self-dosing of CBD has on the severity of DD. Methods: Adult participants (18–75 years of age) who
-
Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants Med. Cannabis Cannabinoids Pub Date : 2023-02-08 Andrea Treyer, Jakob K. Reinhardt, Daniela Elisabeth Eigenmann, Mouhssin Oufir, Matthias Hamburger
Introduction: Treatment with cannabis extracts for a variety of diseases has gained popularity. However, differences in herb-drug interaction potential of extracts from different plant sources are poorly understood. In this study, we provide a characterization of cannabis extracts prepared from four cannabis chemotypes and an in vitro assessment of their Cytochrome P450 (CYP)-mediated herb-drug interaction
-
Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants Med. Cannabis Cannabinoids Pub Date : 2023-02-08
Introduction: Treatment with cannabis extracts for a variety of diseases has gained popularity. However, differences in herb-drug interaction potential of extracts from different plant sources are poorly understood. In this study, we provide a characterization of cannabis extracts prepared from four cannabis chemotypes and an in vitro assessment of their Cytochrome P450 (CYP)-mediated herb-drug interaction
-
Management of Chronic Anal Fissure with a Novel Topical Hemp-Herbal-Based Ointment: A Pilot Study Med. Cannabis Cannabinoids Pub Date : 2023-02-03 Edward Ram, Yaniv Zager, Raanan Meyer, Dan Carter, Samia Joubran, Nir Horesh
Introduction: Anal fissure (AF) is a common anorectal disease. Although several pharmacological treatments are available, many patients still require surgical interventions. In this study, we aimed to evaluate the efficacy of an ointment based on a multifunctional blend of herbal ingredients including hemp (ProctoFiz) for chronic AF. Methods: A single-arm, questionnaire-based prospective study was
-
Management of Chronic Anal Fissure with a Novel Topical Hemp-Herbal-Based Ointment: A Pilot Study Med. Cannabis Cannabinoids Pub Date : 2023-02-03
Introduction: Anal fissure (AF) is a common anorectal disease. Although several pharmacological treatments are available, many patients still require surgical interventions. In this study, we aimed to evaluate the efficacy of an ointment based on a multifunctional blend of herbal ingredients including hemp (ProctoFiz) for chronic AF. Methods: A single-arm, questionnaire-based prospective study was
-
Cannabis Effects on Driving Performance: Clinical Considerations Med. Cannabis Cannabinoids Pub Date : 2023-01-30 Brianna Costales, Shanna L. Babalonis, Joshua D. Brown, Amie J. Goodin
Med Cannabis Cannabinoids 2023;6:8–14
-
Cannabis Effects on Driving Performance: Clinical Considerations Med. Cannabis Cannabinoids Pub Date : 2023-01-30
Med Cannabis Cannabinoids 2023;6:8–14
-
CANNabinoid Drug Interaction Review (CANN-DIR™) Med. Cannabis Cannabinoids Pub Date : 2023-01-12 Paul T. Kocis, Samuel Wadrose, Ryan Lee Wakefield, Aqib Ahmed, Renata Calle, Rohan Gajjar, Kent E. Vrana
Non-prescription cannabidiol (CBD) and medical marijuana (cannabis) currently do not have US Food and Drug Administration (FDA)-approved prescribing information nor a dedicated resource to evaluate potential cannabinoid drug-drug interactions with other medications. The CANNabinoid Drug Interaction Review (CANN-DIR™) is a free web-based platform that has been developed to screen for potential drug-drug
-
CANNabinoid Drug Interaction Review (CANN-DIR™) Med. Cannabis Cannabinoids Pub Date : 2023-01-12
Non-prescription cannabidiol (CBD) and medical marijuana (cannabis) currently do not have US Food and Drug Administration (FDA)-approved prescribing information nor a dedicated resource to evaluate potential cannabinoid drug-drug interactions with other medications. The CANNabinoid Drug Interaction Review (CANN-DIR™) is a free web-based platform that has been developed to screen for potential drug-drug
-
Integration of Cannabis Extract Tetrahydrocannabinol:Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder Med. Cannabis Cannabinoids Pub Date : 2022-11-22
Multilocular pain syndromes with advanced chronification lead to a significant reduction in the quality of life of patients. The administration of cannabis is currently being discussed in the context of therapy-resistant pain and increasing opiate abuse. In this case study, possible side effects from the administration of a cannabis extract tetrahydrocannabinol:cannabidiol are examined. Furthermore
-
Integration of Cannabis Extract Tetrahydrocannabinol:Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder Med. Cannabis Cannabinoids Pub Date : 2022-11-22
Multilocular pain syndromes with advanced chronification lead to a significant reduction in the quality of life of patients. The administration of cannabis is currently being discussed in the context of therapy-resistant pain and increasing opiate abuse. In this case study, possible side effects from the administration of a cannabis extract tetrahydrocannabinol:cannabidiol are examined. Furthermore
-
Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases? Med. Cannabis Cannabinoids Pub Date : 2022-11-14 Milena de Barros Viana, Pedro Everson Alexandre de Aquino, Débora Estadella, Daniel Araki Ribeiro, Glauce Socorro de Barros Viana
This work is a literature review, presenting the current state of the use of cannabinoids on neurodegenerative diseases. The emphasis is on Parkinson’s (PD) and Alzheimer’s (AD) diseases, the two most prevalent neurological diseases. The review goes from Cannabis sativa and its hundreds of bioactive compounds to Δ9-tetrahydrocannabinol (THC) and mainly cannabidiol (CBD) and their interactions with
-
Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases? Med. Cannabis Cannabinoids Pub Date : 2022-11-14
This work is a literature review, presenting the current state of the use of cannabinoids on neurodegenerative diseases. The emphasis is on Parkinson’s (PD) and Alzheimer’s (AD) diseases, the two most prevalent neurological diseases. The review goes from Cannabis sativa and its hundreds of bioactive compounds to Δ9-tetrahydrocannabinol (THC) and mainly cannabidiol (CBD) and their interactions with
-
The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects Med. Cannabis Cannabinoids Pub Date : 2022-11-04 John S. Markowitz, Ludmila De Faria, Qingchen Zhang, Philip W. Melchert, Reginald F. Frye, Brandon O. Klee, Yuli Qian
Introduction: Cannabidiol (CBD) is a widely utilized nonpsychoactive cannabinoid available as an over-the-counter supplement, a component of medical cannabis, and a prescriptive treatment of childhood epilepsies. In vitro studies suggest CBD may inhibit a number of drug-metabolizing enzymes, including carboxylesterase 1 (CES1). The aim of this study was to evaluate effect of CBD on the disposition
-
The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects Med. Cannabis Cannabinoids Pub Date : 2022-11-04
Introduction: Cannabidiol (CBD) is a widely utilized nonpsychoactive cannabinoid available as an over-the-counter supplement, a component of medical cannabis, and a prescriptive treatment of childhood epilepsies. In vitro studies suggest CBD may inhibit a number of drug-metabolizing enzymes, including carboxylesterase 1 (CES1). The aim of this study was to evaluate effect of CBD on the disposition
-
Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference Med. Cannabis Cannabinoids Pub Date : 2022-10-17 Nicole E. Smolinski, Ruba Sajdeya, Robert Cook, Yan Wang, Almut G. Winterstein, Amie Goodin
The Consortium for Medical Marijuana Clinical Outcomes Research, a multi-university collaboration established by the state of Florida in the USA, hosted its second annual Cannabis Clinical Outcomes Research Conference (CCORC) in May 2022. CCORC was held as a hybrid conference, with a scientific program consisting of in-person and virtual sessions. CCORC fostered and disseminated current research on
-
Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference (CCORC) Orlando, FL, USA, May 19-20, 2022 Med. Cannabis Cannabinoids Pub Date : 2022-10-17
Med Cannabis Cannabinoids 2022;5:142–158
-
Cannabinoid Conference 2022 Med. Cannabis Cannabinoids Pub Date : 2022-10-17
Med Cannabis Cannabinoids 2022;5:159–198
-
Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference Med. Cannabis Cannabinoids Pub Date : 2022-10-17
The Consortium for Medical Marijuana Clinical Outcomes Research, a multi-university collaboration established by the state of Florida in the USA, hosted its second annual Cannabis Clinical Outcomes Research Conference (CCORC) in May 2022. CCORC was held as a hybrid conference, with a scientific program consisting of in-person and virtual sessions. CCORC fostered and disseminated current research on
-
Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference (CCORC) Orlando, FL, USA, May 19-20, 2022 Med. Cannabis Cannabinoids Pub Date : 2022-10-17
Med Cannabis Cannabinoids 2022;5:142–158
-
Cannabinoid Conference 2022 Med. Cannabis Cannabinoids Pub Date : 2022-10-17
Med Cannabis Cannabinoids 2022;5:159–198
-
Evaluations of Skin Permeability of Cannabidiol and Its Topical Formulations by Skin Membrane-Based Parallel Artificial Membrane Permeability Assay and Franz Cell Diffusion Assay Med. Cannabis Cannabinoids Pub Date : 2022-10-10 Riley D. Kirk, Toyosi Akanji, Huifang Li, Jie Shen, Saleh Allababidi, Navindra P. Seeram, Matthew J. Bertin, Hang Ma
Introduction: Cannabinoids including cannabidiol (CBD) have attracted enormous interest as bioactive ingredients for various dermatological and/or cosmeceutical uses. However, topical applications of cannabinoids might be limited without a fundamental understanding of their skin permeability. Herein, we aimed to evaluate the skin permeability of CBD and its topical formulations using artificial skin
-
-
Clinical Considerations for Cannabis Use and Cardiovascular Health Med. Cannabis Cannabinoids Pub Date : 2022-09-28 Ruba Sajdeya, Sebastian Jugl, Robert Cook, Joshua D. Brown, Amie Goodin
Med Cannabis Cannabinoids 2022;5:120–127
-
Perspectives on Challenges in Cannabis Drug Delivery Systems: Where Are We? Med. Cannabis Cannabinoids Pub Date : 2022-07-25 Manikandan Palrasu, Lillianne Wright, Manish Patel, Lindsey Leech, Scotty Branch, Shea Harrelson, Saeed Khan
Cannabis and its natural derivatives have emerged as promising therapeutics for multiple pathological and nonpathological medical conditions. For example, cannabinoids, the most popular and biologically active chemicals in cannabis, aid in many clinical ailments, including pain, inflammation, epilepsy, sleep disturbances or insomnia, multiple sclerosis, anorexia, schizophrenia, neurodegenerative diseases
-
Clinical Characteristics and Quality of Life in Adults Initiating Medical Marijuana Treatment Med. Cannabis Cannabinoids Pub Date : 2022-06-03 Lydia S. Buonomano, Matthew M. Mitnick, Thomas R. McCalmont, Paulina Syracuse, Karen L. Dugosh, David S. Festinger, Michelle R. Lent
Introduction: Despite the rising availability and use of medical marijuana (MM) in the USA, little is known about the demographics, clinical characteristics, or quality of life of MM patients. This study describes the demographic characteristics and health-related quality of life (HRQoL) of MM patients who are initiating treatment in Pennsylvania. Methods: Two-hundred adults naive to MM and referred
-
Inhibitory Effects of Cannabinoids on Acetylcholinesterase and Butyrylcholinesterase Enzyme Activities Med. Cannabis Cannabinoids Pub Date : 2022-04-19 Tess Puopolo, Chang Liu, Hang Ma, Navindra P. Seeram
Introduction: Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are two cholinergic enzymes catalyzing the reaction of cleaving acetylcholine into acetate and choline at the neuromuscular junction. Abnormal hyperactivity of AChE and BChE can lead to cholinergic deficiency, which is associated with several neurological disorders including cognitive decline and memory impairments. Preclinical
-
The Effects of Consuming Cannabis Flower for Treatment of Fatigue Med. Cannabis Cannabinoids Pub Date : 2022-04-13 Xiaoxue Li, Jegason P. Diviant, Sarah S. Stith, Franco Brockelman, Keenan Keeling, Branden Hall, Jacob M. Vigil
Objectives: We measure for the first time how commercially available Cannabis flower products affect feelings of fatigue. Methods: A total of 1,224 people recorded 3,922 Cannabis flower self-administration sessions between June 6, 2016, and August 7, 2019, using the Releaf App. Usage sessions included real-time subjective changes in fatigue intensity levels prior to and following Cannabis consumption
-
Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option? Med. Cannabis Cannabinoids Pub Date : 2022-03-22 Walter Zieglgänsberger, Rudolf Brenneisen, Achim Berthele, Carsten T. Wotjak, Borwin Bandelow, Thomas R. Tölle, Beat Lutz
The development of a high-end cannabinoid-based therapy is the result of intense translational research, aiming to convert recent discoveries in the laboratory into better treatments for patients. Novel compounds and new regimes for drug treatment are emerging. Given that previously unreported signaling mechanisms for cannabinoids have been uncovered, clinical studies detailing their high therapeutic
-
Cannx Conference abstracts Med. Cannabis Cannabinoids Pub Date : 2022-03-10
All abstracts are in the attached word document Med Cannabis Cannabinoids 2022;5:36–60
-
Will Cannabis or Cannabinoids Protect You from SARS-CoV-2 Infection or Treat COVID-19? Med. Cannabis Cannabinoids Pub Date : 2022-02-25 Joshua D. Brown, Amie J. Goodin
Med Cannabis Cannabinoids 2022;5:1–4
-
Medicinal Cannabis for the Treatment of Chronic Refractory Pain: An Investigation of the Adverse Event Profile and Health-Related Quality of Life Impact of an Oral Formulation Med. Cannabis Cannabinoids Pub Date : 2022-02-09 Sarah Abelev, Leon N. Warne, Melissa Benson, Mark Hardy, Sunny Nayee, John Barlow
Introduction: Medicinal cannabis is prescribed in Australia for patients with chronic refractory pain conditions. However, measures of safety and effectiveness of different cannabinoids are lacking. We designed an observational study to capture effectiveness, adverse events (AEs), and health-related quality of life (HRQoL) measures in patients prescribed an oral medicinal cannabis formulation at Cannabis
-
A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery Med. Cannabis Cannabinoids Pub Date : 2022-01-18 Stefan Lorenzl, Franz Gottwald, Angelika Nistler, Laura Brehm, Renate Grötsch, Georg Haber, Christian Bremm, Christiane Weck, Carina Trummer, Werner Brand
Introduction: A phase I, open-label clinical trial in healthy male subjects was conducted to assess the pharmacokinetic and safety profile of an oromucosal cannabinoid spray (AP701) containing a lipid-based nanoparticular drug formulation standardized to ∆-9-tetrahydrocannabinol (THC). Methods: Twelve healthy male subjects received a single dose of AP701 (12 sprays) containing 3.96 mg THC. Plasma samples
-
Cannabis for the Treatment of Attention Deficit Hyperactivity Disorder: A Report of 3 Cases Med. Cannabis Cannabinoids Pub Date : 2022-01-13 Holly Mansell, Declan Quinn, Lauren E. Kelly, Jane Alcorn
Attention deficit hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder that is highly prevalent in children and adults. An increasing number of patients with ADHD are self-medicating with cannabis, despite a lack of evidence on efficacy and safety. This case report describes 3 males (ages 18, 22, and 23) who have integrated cannabis into their treatment regimen with positive results
-
Cannabinoids as Cocrystals Med. Cannabis Cannabinoids Pub Date : 2022-01-13 Crist N. Filer
Med Cannabis Cannabinoids 2022;5:1–2
-
Effects of Cannabis on Cardiovascular System: The Good, the Bad, and the Many Unknowns Med. Cannabis Cannabinoids Pub Date : 2021-11-12 Ali E. Dabiri, Ghassan S. Kassab
Cannabis is currently the most consumed illicit substance in the world, and gradual legalization in the USA makes it important to understand the health consequences of the use of this substance. With growing body of evidence that some cannabis ingredients may be beneficial in various aspects of hemostasis, additional research is clearly needed in various clinical areas. In addition to understanding
-
Abstracts of the 2021 Cannabis Clinical Outcomes Research Conference Med. Cannabis Cannabinoids Pub Date : 2021-09-21 R. Brenneisen
Med Cannabis Cannabinoids
-
Proceedings of the 2021 Cannabis Clinical Outcomes Research Conference Med. Cannabis Cannabinoids Pub Date : 2021-09-10 Amie J. Goodin, Debbie L. Wilson, Robert L. Cook, Yan Wang, Joshua Brown, Almut G. Winterstein
The Cannabis Clinical Outcomes Research Conference (CCORC) 2021 was held virtually on April 8 and 9, 2021. The conference was hosted by the Consortium for Medical Marijuana Clinical Outcomes Research, a research organization instituted by the state legislature of Florida in the United States. The inaugural annual CCORC 2021 was organized as a scientific meeting to foster and disseminate research on
-
Measuring the Change in Health-Related Quality of Life in Patients Using Marijuana for Pain Relief Med. Cannabis Cannabinoids Pub Date : 2021-08-12 Andrew M. Peterson, Christine Le, Tyler Dautrich
Introduction: Current evidence suggests that cannabinoids are safe with minimal side effects and are effective in managing chronic pain. Data also show that medical marijuana (MM) may improve quality of life (QoL) among patients. However, there are little data showing the health-related QoL (HRQoL) benefit in MM patients using it for pain. The purpose of this study was to determine if there is a relationship
-
Priorities for Medical Marijuana Research from the Perspective of Physicians, Dispensary Owners/Staff, and Patients: A Survey Study Med. Cannabis Cannabinoids Pub Date : 2021-08-02 Jennifer Jean-Jacques, Robert Cook, Almut G. Winterstein, Amie Goodin, Joshua D. Brown, Sebastian Jugl, Yan Wang
Objective: More patients are turning to medical marijuana as an alternative treatment, yet there are apparent knowledge gaps on the risk benefit of medical marijuana for a variety of indications. This study aimed to determine the priorities for medical marijuana research from the perspective of multiple stakeholders including patients, clinicians, and industry representatives. Methods: An anonymous
-
The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines Med. Cannabis Cannabinoids Pub Date : 2021-07-29 Ryan F. Maguire, Daniel J. Wilkinson, Timothy J. England, Saoirse E. O’Sullivan
Introduction: Cannabidiol (CBD) can be isolated from Cannabis sativa L. or synthetically produced. The aim of this study was to compare the in vitro effects of purified natural and synthetic CBD to establish any pharmacological differences or superiority between sources. Methods: Six purified samples of CBD were obtained, 4 of these were natural and 2 synthetic. The anticancer effects of CBD were assessed
-
Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease Med. Cannabis Cannabinoids Pub Date : 2021-06-21 Kaleb Bogale, Wesley Raup-Konsavage, Shannon Dalessio, Kent Vrana, Matthew D. Coates
For centuries, cannabis and its components have been used to manage a wide variety of symptoms associated with many illnesses. Gastrointestinal (GI) diseases are no exception in this regard. Individuals suffering from inflammatory bowel disease (IBD) are among those who have sought out the ameliorating properties of this plant. As legal limitations of its use have eased, interest has grown from both
-
Much Ado about Dosing: The Needs and Challenges of Defining a Standardized Cannabis Unit Med. Cannabis Cannabinoids Pub Date : 2021-06-17 Sebastian Jugl, Ruba Sajdeya, Earl J. Morris, Amie J. Goodin, Joshua D. Brown
Med Cannabis Cannabinoids
-
Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence Med. Cannabis Cannabinoids Pub Date : 2021-05-21 Rishabh Verma, Farazul Hoda, Mawrah Arshad, Asif Iqubal, Ali Nasir Siddiqui, Mohammad Ahmed Khan, Syed Ehtaishamul Haque, Mohd Akhtar, Abul Kalam Najmi
Cannabis sativa L. is an annual herbaceous dioecious plant which was first cultivated by agricultural human societies in Asia. Over the period of time, various parts of the plant like leaf, flower, and seed were used for recreational as well as therapeutic purposes. The main chemical components of Cannabis sativa are termed as cannabinoids, among them the key psychoactive constituent is Δ-9-tetrahydrocannabinol
-
Perinatal Cannabis Exposures and Autism Spectrum Disorders Med. Cannabis Cannabinoids Pub Date : 2021-05-05 Ruba Sajdeya, Joshua D. Brown, Amie J. Goodin
Med Cannabis Cannabinoids
-
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019 Med. Cannabis Cannabinoids Pub Date : 2021-02-25 Sebastian Jugl, Aimalohi Okpeku, Brianna Costales, Earl J. Morris, Golnoosh Alipour-Haris, Juan M. Hincapie-Castillo, Nichole E. Stetten, Ruba Sajdeya, Shailina Keshwani, Verlin Joseph, Yahan Zhang, Yun Shen, Lauren Adkins, Almut G. Winterstein, Amie Goodin
In 2017, a National Academies of Sciences, Engineering, and Medicine (NASEM) report comprehensively evaluated the body of evidence regarding cannabis health effects through the year 2016. The objectives of this study are to identify and map the most recently (2016–2019) published literature across approved conditions for medical cannabis and to evaluate the quality of identified recent systematic reviews
-
Introducing Commentary Series: “Evidence in Context” Med. Cannabis Cannabinoids Pub Date : 2021-02-23 Amie J. Goodin, Almut G. Winterstein, Robert C. Cook, Yan Wang, Joshua D. Brown
Med Cannabis Cannabinoids
-
Evidence in Context: High Risk of Bias in Medical Cannabis and Cannabinoid Clinical Trials Dictates the Need for Cautious Interpretation Med. Cannabis Cannabinoids Pub Date : 2021-02-19 Joshua D. Brown, Amie J. Goodin
Med Cannabis Cannabinoids
-
Demographics, Perceptions, and Use of Medical Marijuana among Patients in Florida Med. Cannabis Cannabinoids Pub Date : 2020-12-22 Martha S. Rosenthal, R. Nathan Pipitone
Medical marijuana (MMJ) is currently legal in 35 US states, with an estimated 3.6 million state-legal medical cannabis patients. Although there are currently over 440,000 MMJ patients in the state of Florida, there are limited data on their demographics, reasons and patterns of use, and successes or failures of treatment. The goal of this study is to examine the demographics, perceptions, and use of